Clinical trial shows once-daily oral medication may benefit patients with chronic heart failure
Nearly 7 million people in the United States live with heart failure—and that incidence is expected to climb in the coming decades. LUMINARA, a new phase 2b clinical trial led by James Januzzi, a cardiologist from the Mass General Brigham Heart and Vascular Institute and Baim Institute for Clinical Research, sheds light on the use of the investigational oral medication AZD5462, designed to…
A new clinical trial highlights the potential benefits of a once-daily oral medication in patients with chronic heart failure. James Januzzi, a cardiologist from the Mass General Brigham Heart and Vascular Institute, led the LUMINARA study, which involved 375 participants from 57 centers in 10 countries. The investigational drug, AZD5462, developed by AstraZeneca, aims to improve cardiac remodeling and blood flow in heart failure patients.
The double-blind, placebo-controlled trial found that AZD5462 was well tolerated and reduced end-systolic volume index when paired with current standard-of-care therapies. The 20 mg dose provided the most significant benefit with minimal side effects. While the trial results are promising, larger studies are needed to determine the long-term clinical benefits of this oral relaxin therapy.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
